Detalhe da pesquisa
1.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870973
2.
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
N Engl J Med
; 386(3): 241-251, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534430
3.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35729418
4.
A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries.
Future Oncol
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031886
5.
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Future Oncol
; 19(2): 123-135, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877099
6.
Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply.
N Engl J Med
; 390(4): 381-382, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265654
7.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
8.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol
; 17(23): 3007-3016, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34156285
9.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol
; 17(7): 763-773, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150799
10.
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Support Care Cancer
; 29(1): 117-125, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32318871
11.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28586279
12.
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Br J Cancer
; 121(3): 283, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31235866
13.
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.
Future Oncol
; 15(18): 2139-2149, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185741
14.
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Br J Cancer
; 119(8): 950-960, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30318514
15.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Br J Cancer
; 116(12): 1505-1512, 2017 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28463960
16.
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
Eur Respir J
; 50(2)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28798088
17.
Alectinib for treatment of ALK-positive non-small-cell lung cancer.
Future Oncol
; 13(4): 321-335, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27780368
18.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24933332
19.
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Eur Respir J
; 46(6): 1773-80, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493785
20.
Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.
BMC Cancer
; 14: 989, 2014 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25527907